Intrinsiqq
Faeth Therapeutics, Inc. logo

Faeth Therapeutics, Inc. Insider Trading

SNSE

Compare
Last 12 months

Insiders bought $1.19M on the open market and sold nothing.

Net open-market
+$1.19M
4 buys · 0 sales
Under a 10b5-1 plan
—
no sales
Insiders who bought / sold
2 / 0
executives and directors
Last open-market buy
Jul 2026
Jul 1, 2026

Get an email when SNSE's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Jun 29 – Jul 1
    Brian C Stephenson
    Chief Financial Officer · bought 13,634 at avg $23.92
    326K
    41% of stake
  • Jun 24 – 26
    Brian C Stephenson
    Chief Financial Officer · bought 15,641 at avg $25.65
    401K
    90% of stake
  • Jun 22 – 23
    Brian C Stephenson
    Chief Financial Officer · bought 17,413 at avg $23.31
    406K
    New position
  • Jun 22
    Anand Kiran Parikh
    President and CEO · bought 2,806 at $19.76
    55K
    0.3% of stake
  • Jun 1No plan
    Cambrian Biopharma Inc
    Large holder · sold 25,000 at avg $20.02
    501K
    16% of stake
  • Jun 1No plan
    James Peyer
    Large holder · sold 25,000 at avg $20.02
    501K
    16% of stake
  • Apr 2 – 7No plan
    ICS Opportunities II LLC
    Large holder · sold 17,076 at avg $31.51
    538K
    11% of stake
  • Apr 2 – 7
    ICS Opportunities II LLC
    Large holder · bought 4,215 at avg $33.54
    141K
    3.2% of stake
  • Mar 31 – Apr 1No plan
    Millennium Management LLC
    Large holder · sold 2,741 at avg $28.07
    77K
    1.8% of stake
  • Mar 31 – Apr 1
    Millennium Management LLC
    Large holder · bought 12,180 at avg $31.37
    382K
    9.0% of stake
  • Mar 26 – 30No plan
    ICS Opportunities II LLC
    Large holder · sold 3,250 at avg $27.51
    89K
    2.2% of stake
  • Mar 26 – 30
    ICS Opportunities II LLC
    Large holder · bought 30,585 at avg $26.75
    818K
    27% of stake
  • Dec 9, 2025No plan
    Cambrian Biopharma Inc
    Large holder · sold 6,612 at avg $8.25
    55K
    4.1% of stake
  • Dec 8, 2025 – Dec 9, 2025No plan
    James Peyer
    Large holder · sold 6,612 at avg $8.25
    55K
    4.1% of stake
  • Dec 4, 2025 – Dec 5, 2025No plan
    Cambrian Biopharma Inc
    Large holder · sold 21,295 at avg $10.93
    233K
    12% of stake
  • Dec 4, 2025 – Dec 5, 2025No plan
    James Peyer
    Large holder · sold 21,295 at avg $10.93
    233K
    12% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SNSE, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with SNSE

CompareIntrinsic value
STOKStoke Therapeutics Inc.
$26.73-0.74%25
CTNMContineum Therapeutics, Inc.
$8.68-3.98%10
CORTCorcept Therapeutics Incorporated
$63.62-2.09%56
ALKSAlkermes plc
$44.94-2.69%36
JAZZJazz Pharmaceuticals plc
$230.26-2.62%58
AXSMAxsome Therapeutics, Inc.
$129.36-4.66%10
TVTXTravere Therapeutics Inc.
$47.00-2.69%52
SNDXSyndax Pharmaceuticals Inc.
$8.72-4.49%0

Held by ETFs

SNSE is in 2 US ETFs. The largest of them, with SNSE's weight in each:

Spot a number that looks wrong? Check it in SNSE's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing SNSE

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.